Can Glucagon Reverse the Role of Beta Blocker Overdose in Peptide Therapy?
Title: Can Glucagon Reverse the Role of Beta Blocker Overdose in Peptide Therapy? Abstract: Glucagon, a 29-amino acid peptide, serves as a critical antidote in beta-blocker overdose by bypassing blocked β-receptors to activate adenylate cyclase, increasing cardiac contractility. In peptide therapy, glucagon’s role highlights the therapeutic utility of peptide hormones in toxicology. Current market trends show a 12.5% CAGR in peptide therapeutics (2023–2030), driven by cardiovascular applications. Compared to synthetic catecholamines, glucagon offers unique inotropic benefits but has limitations (short half-life, hyperglycemia risk). Key brands (e.g., Novo Nordisk’s GlucaGen) dominate, while regulatory certifications (FDA, GMP) ensure quality. Selection criteria prioritize purity (>98%) and stability. Logistics require cold-chain storage (2–8°C). Industry data supports glucagon’s efficacy in overdose reversal, underscoring peptide therapy’s expanding role in emergency medicine.